Krystal Biotech, Inc. believes it is positioned to deliver the first genetically corrective treatment to patients with the rare and debilitating genetic skin disease dystrophic epidermolysis bullosa (DEB), following a successful Phase III study testing its topical gene therapy Vyjuvek (beremagene geperpavec, B-VEC), showing a benefit on wound healing compared to placebo.
The data from the pivotal GEM-3 trial, announced on 29 November, represent the first pivotal data to be released by Krystal and help validate the company's broader pipeline ambitions
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?